On the contrary, ESA hyporesponsiveness was decreased by concomitant use of iron preparations (OR = 0.3, 95% CI: 0.2–0.7; P-value = 0.002) and high dosage of ACE inhibitors/ARBs (OR = 0.5, 95% CI: 0.3–0.9; P-value = 0.022) in CKD patients and by higher levels of albumin and potassium in cancer patients, although not significantly (P-values> 0.005). Here, ACE is linked to cancer.